Emerging Markets

© Getty Images

J&J’s Akeega FDA approval to heat up PARP battle

By Isabel Cameron

The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic castration-resistant prostate cancer (mCRPC).

© Getty Images

MaaT Pharma joins Microbiome Therapeutics Innovation Group

By Isabel Cameron

MaaT Pharma, a clinical-stage biotech company focused on the development of Microbiome Ecosystem Therapies (MET) dedicated to improving survival outcomes for patients with cancer, is now a member of Microbiome Therapeutics Innovation Group (MTIG).

© Getty Images

SMi discloses £6 million seed funding round

By Isabel Cameron

SMi Systems, a company specializing in single molecule imaging and quantification technologies, has disclosed a £6m seed funding round to develop the utility of a novel multi-omic platform for in vitro diagnosis and biomedical research.

Follow us

Webinars